← Leaderboards
Cary O. Harding
Oregon Health And Science University
$9,584,438
Attributed
$9,762,037
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–23$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$17,645,415 · 14
By mechanism
U54$9,515,493 · 5
R01$6,387,181 · 3
M01$778,399 · 2
R43$355,198 · 1
R21$298,452 · 1
R41$186,449 · 1
Top collaborators
- Daniel Fred Carlson1 shared
Others in their field
Top investigators on “Hyperphenylalaninaemias”
- Georgianne L Arnold · University Of Rochester$4,989,983
- Kiran Musunuru · University Of Pennsylvania$4,332,527
- Eileen K Jaffe · Institute For Cancer Research$1,562,710
- Donald Lee Granger · University Of Utah$1,453,214
- Shirley Luckhart · Virginia Polytechnic Inst And St Univ$1,092,410
- Jeffrey A Riffell · University Of Washington$1,092,410
Research focus
HyperphenylalaninaemiasPhenylalanineClinical ResearchGene TherapyBloodEvaluationEnzymesPhenylketonuriasLiverAdultFutureInborn Errors Of MetabolismTetrahydrobiopterinNeonatal ScreeningEnzyme DeficiencyPhenylalanine HydroxylaseChronicAdolescentMediatingProteinsDietMouse ModelRestorationRare Diseases
Grant awards (52)
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network$1,523,839
U54 · FY2023 · HD · contact PI
Administrative Core$179,268
U54 · FY2023 · HD · contact PI
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia$121,848
U54 · FY2023 · HD · contact PI
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network$1,536,308
U54 · FY2022 · HD · contact PI
Administrative Core$187,601
U54 · FY2022 · HD · contact PI
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia$121,847
U54 · FY2022 · HD · contact PI
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network$1,548,508
U54 · FY2021 · HD · contact PI
Administrative Core$199,800
U54 · FY2021 · HD · contact PI
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia$121,848
U54 · FY2021 · HD · contact PI
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network$1,567,686
U54 · FY2020 · HD · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$383,779
R01 · FY2020 · NS · contact PI
Administrative Core$205,960
U54 · FY2020 · HD · contact PI
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia$121,848
U54 · FY2020 · HD · contact PI
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network$1,707,037
U54 · FY2019 · HD · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$383,779
R01 · FY2019 · NS · contact PI
Administrative Core$227,810
U54 · FY2019 · HD · contact PI
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia$144,285
U54 · FY2019 · HD · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$383,779
R01 · FY2018 · NS · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$383,779
R01 · FY2017 · NS · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$397,279
R01 · FY2016 · NS · contact PI
Development and Characterization of a Swine Model of Phenylketonuria$355,198
R43 · FY2016 · OD
Novel therapy for monoamine neurotransmitter deficiency in PKU$336,389
R01 · FY2015 · NS · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$333,026
R01 · FY2014 · NS · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$324,616
R01 · FY2013 · NS · contact PI
Augmented Phenylalanine Clearance by Muscles as Novel Therapy for Phenylketonuria$316,309
R01 · FY2013 · HD · contact PI
Novel therapy for monoamine neurotransmitter deficiency in PKU$399,658
R01 · FY2012 · NS · contact PI
Augmented Phenylalanine Clearance by Muscles as Novel Therapy for Phenylketonuria$326,776
R01 · FY2012 · HD · contact PI
Augmented Phenylalanine Clearance by Muscles as Novel Therapy for Phenylketonuria$325,247
R01 · FY2011 · HD · contact PI
Augmented Phenylalanine Clearance by Muscles as Novel Therapy for Phenylketonuria$328,528
R01 · FY2010 · HD · contact PI
Augmented Phenylalanine Clearance by Muscles as Novel Therapy for Phenylketonuria$335,682
R01 · FY2009 · HD · contact PI
AAV2/8 vector-mediated liver gene therapy for phenylketonuria (PKU)$279,677
R01 · FY2009 · DK · contact PI
AAV2/8 vector-mediated liver gene therapy for phenylketonuria (PKU)$279,677
R01 · FY2008 · DK · contact PI
AAV2/8 vector-mediated liver gene therapy for phenylketonuria (PKU)$285,174
R01 · FY2007 · DK · contact PI
Liver gene therapy for murine phenyketonuria (PKU)$284,067
R01 · FY2006 · DK · contact PI
Intravenous non-viral gene therapy for phenylketonuria (PKU)$186,449
R41 · FY2006 · DK · contact PI
Stem Cell-Mediated Liver Repopulation for Murine PKU$147,452
R21 · FY2006 · HL · contact PI
Stem Cell-Mediated Liver Repopulation for Murine PKU$151,000
R21 · FY2005 · HL
DHA TRIGLYCERIDE SUPPLEMENTATION IN LCHADD PATIENTS$16,168
M01 · FY2005 · RR
DHA Triglyceride Supplementation in LCHADD Patients$18,943
M01 · FY2004 · RR
Docosahexaenoic acid triglyceride supplementation in LCHADD$172,411
M01 · FY2002 · RR
Docosahexaenoic acid triglyceride supplementation in LCHADD$172,411
M01 · FY2002 · RR
Metabolic Engineering as Therapy for Murine PKU$151,000
R01 · FY2002 · DK
DHA TRIGLYCERIDE SUPPLEMENTATION IN LONG CHAIN DEHYDROGENASE DEFICIENCY (LCHADD)$106,600
M01 · FY2002 · RR
Docosahexaenoic acid triglyceride supplementation in LCHADD$172,411
M01 · FY2001 · RR
Metabolic Engineering as Therapy for Murine PKU$148,960
R01 · FY2001 · DK
DHA TRIGLYCERIDE SUPPLEMENTATION IN LONG CHAIN DEHYDROGENASE DEFICIENCY (LCHADD)$106,600
M01 · FY2001 · RR
DHA TRIGLYCERIDE SUPPLEMENTATION IN LONG CHAIN DEHYDROGENASE DEFICIENCY (LCHADD)$12,855
M01 · FY2001 · RR
Docosahexaenoic acid triglyceride supplementation in LCHADD$0
M01 · FY2001 · RR
HETEROLOGOUS GENE THERAPY FOR METABOLISM$124,243
K08 · FY2000 · DK
DHA TRIGLYCERIDE SUPPLEMENTATION IN LONG CHAIN DEHYDROGENASE DEFICIENCY (LCHADD)$0
M01 · FY2000 · RR
DHA TRIGLYCERIDE SUPPLEMENTATION IN LONG CHAIN DEHYDROGENASE DEFICIENCY (LCHADD)$0
M01 · FY2000 · RR
Docosahexaenoic acid triglyceride supplementation in LCHADD$0
M01 · FY2000 · RR